JP6768705B2 - 創傷被覆材用の組成物 - Google Patents
創傷被覆材用の組成物 Download PDFInfo
- Publication number
- JP6768705B2 JP6768705B2 JP2017557505A JP2017557505A JP6768705B2 JP 6768705 B2 JP6768705 B2 JP 6768705B2 JP 2017557505 A JP2017557505 A JP 2017557505A JP 2017557505 A JP2017557505 A JP 2017557505A JP 6768705 B2 JP6768705 B2 JP 6768705B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- component
- tribasic
- chitosan
- solubilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 135
- 239000002253 acid Substances 0.000 claims description 221
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 126
- 239000004135 Bone phosphate Substances 0.000 claims description 117
- 229920001661 Chitosan Polymers 0.000 claims description 107
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 64
- 206010052428 Wound Diseases 0.000 claims description 46
- 208000027418 Wounds and injury Diseases 0.000 claims description 46
- 239000004310 lactic acid Substances 0.000 claims description 32
- 235000014655 lactic acid Nutrition 0.000 claims description 32
- 229920002101 Chitin Polymers 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000012876 carrier material Substances 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000006196 deacetylation Effects 0.000 claims description 6
- 238000003381 deacetylation reaction Methods 0.000 claims description 6
- 230000002147 killing effect Effects 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229940012413 factor vii Drugs 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 239000004627 regenerated cellulose Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 230000001937 non-anti-biotic effect Effects 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000011044 succinic acid Nutrition 0.000 claims 1
- 239000000835 fiber Substances 0.000 description 60
- 239000000463 material Substances 0.000 description 39
- 238000012360 testing method Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
- 244000005700 microbiome Species 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 239000002904 solvent Substances 0.000 description 18
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 230000003381 solubilizing effect Effects 0.000 description 16
- 150000007513 acids Chemical class 0.000 description 14
- 239000003929 acidic solution Substances 0.000 description 13
- 239000007195 tryptone soya broth Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229920000297 Rayon Polymers 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- -1 hydrogen ions Chemical class 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 239000002874 hemostatic agent Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000004584 polyacrylic acid Substances 0.000 description 6
- 229910052709 silver Inorganic materials 0.000 description 6
- 239000004332 silver Substances 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 5
- 229940030225 antihemorrhagics Drugs 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 229920005830 Polyurethane Foam Polymers 0.000 description 4
- 230000032770 biofilm formation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 239000011496 polyurethane foam Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920006264 polyurethane film Polymers 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002413 Polyhexanide Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000007521 triprotic acids Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00927—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
- A61F2013/00931—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors chitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(a)繊維状の第1の成分の少なくとも一部分を、少なくとも1種の三塩基酸及び少なくとも1種の可溶化酸を含む混合物で被覆する工程と、及び/または
(b)第1の成分の少なくとも一部分に、少なくとも1種の三塩基酸及び少なくとも1種の可溶化酸を含む混合物を吸収させる工程とを含む。
(a)水及び/または溶剤に三塩基酸を混合して三塩基酸溶液を得る工程と、
(b)水及び/または溶剤に可溶化酸を混合することにより調製した可溶化酸溶液に、三塩基酸溶液を混合して、混合酸性溶液を得る工程と、
(c)任意に、溶剤に混合酸性溶液を混合する工程と、
(d)工程(c)で得られた溶液に繊維状の第1の成分を加える工程とを含む。
一般的な方法1:第1の成分と三塩基酸
三塩基酸(例えばクエン酸)粉末を脱イオン水に溶解し、次に非水性の溶剤(例えばIPA)と混合した。第1の成分は、典型的には不織繊維の形態であり、三塩基酸溶液中に配置して、溶液を吸収させた。次に溶液を加熱乾燥を用いて乾燥し、三塩基酸で被覆した固体のキトサン、キチンまたはこれらの誘導体を残存させた。
三塩基酸(例えばクエン酸)粉末を脱イオン水に溶解し、次に可溶化酸(例えば乳酸)溶液と混合した。これを続いて非水性溶剤(例えばIPA)と混合した。第1の成分は、典型的には不織繊維の形態であり、混合酸性溶液中に配置して、溶液を吸収させた。次に溶液を加熱乾燥を用いて乾燥し、三塩基酸と可溶化酸との混合物で被覆した固体のキトサン、キチンまたはこれらの誘導体を残存させた。
以下、本発明に従って調製された組成物の実施例である。
実施例14(参考例):本発明の組成物は、0.6gのクエン酸を入れた8gの脱イオン水の中に、公称2gの100%キトサン不織繊維を含んで調製する。組成物は、非網目状の(non-reticulated)ポリウレタンフォームの表面上に被覆し、乾燥させた。本発明の乾燥した組成物を含むフォームは、次にポリウレタンフォームに接着剤で結合され、結合されたポリウレタンフィルム層より遠位に、創傷接触層が形成された。
さまざまな微生物のバイオフィルムに対する抗菌効能を測定するために、MBEC (最小バイオフィルム形成阻止濃度、Minimum Biofilm Eradication Concentration)アッセイを使用した。
緑膿菌ATCC13359
スタフィロコッカス−ヘモリチカス
MRSA308。
対照(Control):リン酸緩衝食塩水
試料(Sample)A:銀入り(公称1%)100%キトサン不織繊維と乳酸より得られた、公称25%一塩基酸組成物
試料B:銀入り(公称1%)カルボキシメチル化セルロース不織繊維(Aquacel Ag[登録商標])
試料C:乳酸入り100%キトサン不織繊維より得られた、公称25%一塩基酸組成物
試料D:酢酸入り100%キトサン不織繊維より得られた、公称25%一塩基酸組成物
試料E:クエン酸入り100%キトサン不織繊維より得られた、公称25%三塩基酸組成物。
各微生物の24時間培養物は、トリプトンソーヤ寒天培地(Tryptone Soya Agar (TSA))プレートまたは ブレインハートインフュージョン寒天培地(Brain Heart Infusion Agar (BHIA))プレートのいずれかから採取され、20mlのトリプトンソーヤブイヨン培地(Tryptone Soya Broth (TSB))または20mlのブレインハートインフュージョンブイヨン培地(Brain Heart Infusion Broth (BHIB))のいずれかの中に懸濁させた。その結果得られたバクテリア懸濁液を希釈して、108cfuml-1のバクテリア濃度に対応する初期OD590 = 0.10 ± 0.03を得た。この初期の種菌は、次第に低くなる細菌量(すなわち107, 106, 105, 104, 103 cfuml-1)が表れるように、6回連続して希釈された。各生物の開始時のバクテリア濃度は、典型的には 1 x 108± 5 x 107cfuml-1だった。
各微生物のバイオフィルムは、マイクロタイタープレートのピンふた突起(pin lid projections)上で48時間、37℃、50rmpで育成した。48時間後、ピンふたを取り外して、リン酸緩衝食塩水で短時間洗浄してプランクトン状のバクテリアを除去し、続いて薬剤チャレンジプレート(agent challenge plate)中に24時間配置した。創傷被覆材用のチャレンジプレートの調製のために、無菌のはさみを使用して1cm2 の断片が切り取られ、マイクロタイタープレートの指定されたウェル内に配置された。顆粒の試験薬剤用のチャレンジプレートは、マイクロタイタープレートのウェル内に各顆粒製剤を30mg ± 3mgに量り分けることにより調製した。次に創傷被覆材及び顆粒を150μlのPBSにより活性化した。処理に続いて、残った付着バクテリアを回収するために、ピンふた突起をPBS内で2回洗浄し、次に200μlの中和剤中に移し、音波水浴(sonic water-bath)中に5分間配置した。連続希釈が得られた回収液(recovery broth)について実行され、ドロッププレート(drop plate)が回収したバクテリアの量を計るために使用された。全ての試料は、特に明記しない限り、三回試験された(tested in triplicate)。
スタフィロコッカス−ヘモリチカスNCTC11042
緑膿菌ATCC10434
メチシリン耐性黄色ブドウ球菌308。
対照:リン酸緩衝食塩水(PBS)
試料F:15%乳酸及び3%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.2g及びクエン酸0.04g(実施例8)と同等である
試料G:15%乳酸及び25%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.2g及びクエン酸0.34g(実施例9)と同等である
試料H:20%乳酸及び60%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.27g及びクエン酸0.81g(実施例10)と同等である
試料I:3%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g及びクエン酸0.04g(参考実施例2)と同等である
試料J:25%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g及びクエン酸0.34g(参考実施例3)と同等である
試料K:60%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g及びクエン酸0.81g(参考実施例4)と同等である。
試験バクテリアの24時間培養物は、トリプトンソーヤ寒天培地(TSA)プレートから無菌綿棒を使用して採取され、20mlのトリプトンソーヤブイヨン培地(TSB)の中に再懸濁させた。バクテリア懸濁液を希釈して、108± 5 x107cfuml-1のバクテリア濃度に対応する、初期OD590 = 0.10 ± 0.03を得た。これをさらにTSB内で希釈して、試験材を含むCDCリアクターのための種菌として使用した。CDCリアクターを、バイオフィルムの成長を促すために50rpmで振盪しながら、37℃で48時間培養した。
48時間後、試験材をCDCリアクターから取り外し、プランクトン状のバクテリアを除去するために無菌PBS内で3回洗浄した。次に洗浄した試験材を2枚の1.5 cm2 創傷被覆材の間に試験材を挟むことにより処理した。試験に先立って、各1.5 cm2 断片に350μlPBS(75%飽和)を添加することにより、被覆材を活性化した。対照材は、緑膿菌用に2mlのPBSの中(あるいはスタフィロコッカス−ヘモリチカス及びMRSAの場合は2mlPBS+0.1%TSBの中)に浸水した。全ての試料を3回試験した。微生物は、24時間の処理後に試験材から回収し、連続希釈とドロッププレートを実行して量を計った。
2種のバクテリア種に対する6種類の創傷被覆材のバイオフィルム除去能力を測定するために、CDCリアクター方法を使用した。
スタフィロコッカス−ヘモリチカスNCTC8325
緑膿菌ATCC10434。
対照:リン酸緩衝食塩水(PBS)
試料L:25%乳酸及び30%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.34g及びクエン酸0.41g(実施例11)と同等である
試料M:25%乳酸及び40%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.34g及びクエン酸0.54g(実施例12)と同等である
試料N:30%乳酸及び40%クエン酸を含む100%キトサン不織繊維。これはキトサン1.35g、乳酸0.41g及びクエン酸0.54g(実施例13)と同等である
試料O:100%キトサン不織繊維
試料P:25%乳酸を含む55%キトサン繊維/45%ビスコース不織繊維。これはキトサン0.74g、ビスコース0.61g及びクエン酸0.34gと同等である
試料Q:イオン状態の銀含有物(ionic silver-containing)を含む不織カルボキシメチル化セルロース、抗バイオフィルム製剤。
各微生物の24時間培養物は、トリプトンソーヤ寒天培地(TSA)プレートから採取され、20mlのトリプトンソーヤブイヨン培地(TSB)の中に再懸濁させた。その結果得られたバクテリア懸濁液を希釈して、108 ± 5 x107cfuml-1のバクテリア濃度に対応する、初期OD590 = 0.10 ± 0.03を得た。これをさらにTSB中で約107 cfuml-1まで希釈し、CDCリアクター用の初期種菌として使用した。CDCリアクターを、バイオフィルムの成長を促すために50rpmで振盪しながら、37℃で24時間及び72時間培養した。
24時間後及び72時間後、試験材をCDCリアクターから取り外して、プランクトン状のバクテリアを除去するために、無菌リン酸緩衝食塩水(PBS)中で3回洗浄した。次に洗浄した試験材を2枚の創傷被覆材の間に試験材を挟むことにより処理した。試験に先立って、1%のTSBを含む350μlのPBSを添加することにより、被覆材を活性化した。対照の試験材は、1%のTSBを含む2mlのPBS中に浸水した。24時間の処理時間に続いて、試験材は2mlの中和剤中に配置され、15分間超音波処理されて、残った付着バクテリアを再生した。連続希釈が得られた回収液(recovery broth)について実行され、ドロッププレート(drop plate)が回収したバクテリアの量を計るために使用された。全ての試料について試験は3回行われた。
Claims (18)
- キトサン、キチン、キトサン誘導体、キチン誘導体、及びこれらの任意の組み合わせからなる群から選択された繊維状の第1の成分と、少なくとも1種の三塩基酸と、少なくとも1種の可溶化酸とを含み、前記少なくとも1種の三塩基酸と前記少なくとも1種の可溶化酸とは、前記第1の成分の少なくとも一部分の上に被覆され、及び/または前記第1の成分の少なくとも一部分の中に吸収されている組成物。
- 前記第1の成分は非抗菌であり、該非抗菌は24時間以内にlog4のバクテリア殺し率を実証する薬剤または物質を指す請求項1に記載の組成物。
- 前記少なくとも1種の三塩基酸に対する前記第1の成分の比率は少なくとも2:1であり、及び/または前記少なくとも1種の可溶化酸に対する前記少なくとも1種の三塩基酸の比率は少なくとも1:1である請求項1または2に記載の組成物。
- 前記第1の成分はキトサンであり、及び/または前記三塩基酸はクエン酸である請求項1乃至3のいずれか1項に記載の組成物。
- 前記第1の成分は、70%を超える脱アセチル化度を有し、及び/または前記第1の成分は、1%酢酸溶液中で150cpsを超える粘度を有する請求項4に記載の組成物。
- 前記三塩基酸は、前記第1の成分の約2から75%の量が存在する請求項1乃至5のいずれか1項に記載の組成物。
- 前記三塩基酸は、前記第1の成分の約25から60%の量が存在する請求項6に記載の組成物。
- 前記可溶化酸は一塩基酸である請求項1乃至7のいずれか1項に記載の組成物。
- 前記一塩基酸は、乳酸、ギ酸、酢酸、塩酸、コハク酸及びこれらの混合からなる群から選択される請求項8に記載の組成物。
- 前記可溶化酸と前記三塩基酸とは、前記第1の成分に接触する前に混合され、及び/または前記可溶化酸及び前記三塩基酸は、前記第1の成分の上に被覆されている請求項1乃至9のいずれか1項に記載の組成物。
- 前記可溶化酸は、前記第1の成分の2から50%の量が存在する請求項1乃至10のいずれか1項に記載の組成物。
- 前記可溶化酸は、前記第1の成分の15から20%の量が存在する請求項11に記載の組成物。
- 前記三塩基酸及び/または前記可溶化酸は、担体材料の上に被覆されている請求項1乃至12のいずれか1項に記載の組成物。
- 抗菌剤、医薬品、キレート剤、湿潤剤、成長因子、サイトカイン、MMP(マトリックスメタロプロテアーゼ)及びエラスターゼのような治癒を遅延させる物質を吸収する薬剤、カルシウム、ビタミンK、フィブリノゲン、トロンビン、第VII因子、第VIII因子、粘土、酸化再生セルロース、ゼラチン及びコラーゲンからなる群から選択された付加的な成分をさらに含む請求項1乃至13のいずれかに1項に記載の組成物。
- 請求項1乃至14のいずれか1項に記載の組成物を含む創傷被覆材。
- 治療薬として使用する請求項1乃至14のいずれか1項に記載の組成物。
- 創傷の治療に使用する、またはバイオフィルムにおけるバクテリアの破壊と殺しに使用する、またはバイオフィルムの形成の防止に使用する請求項1乃至14のいずれか1項に記載の組成物。
- キトサン、キチン、キトサン誘導体、キチン誘導体、及びこれらの組み合わせからなる群から選択された繊維状の第1の成分と、少なくとも1種の三塩基酸と、少なくとも1種の可溶化酸とを含む組成物の製造方法であって、
a.前記繊維状の第1の成分の少なくとも一部分を、前記少なくとも1種の三塩基酸と前記少なくとも1種の可溶化酸とを含む混合物で被覆する工程、及び/または
b.前記第1の成分の少なくとも一部分に、前記少なくとも1種の三塩基酸と前記少なくとも1種の可溶化酸とを含む混合物を吸収させる工程、
を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1501334.5 | 2015-01-27 | ||
GBGB1501334.5A GB201501334D0 (en) | 2015-01-27 | 2015-01-27 | Composition for a wound dressing |
PCT/GB2016/050180 WO2016120622A1 (en) | 2015-01-27 | 2016-01-27 | Composition for a wound dressing |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018502697A JP2018502697A (ja) | 2018-02-01 |
JP2018502697A5 JP2018502697A5 (ja) | 2019-03-07 |
JP6768705B2 true JP6768705B2 (ja) | 2020-10-14 |
Family
ID=52673993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017557505A Active JP6768705B2 (ja) | 2015-01-27 | 2016-01-27 | 創傷被覆材用の組成物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10639202B2 (ja) |
EP (1) | EP3250245B8 (ja) |
JP (1) | JP6768705B2 (ja) |
KR (1) | KR102608165B1 (ja) |
CN (1) | CN107580507A (ja) |
AU (1) | AU2016210993B2 (ja) |
BR (1) | BR112017016100B1 (ja) |
CA (1) | CA2975018A1 (ja) |
DK (1) | DK3250245T3 (ja) |
ES (1) | ES2928794T3 (ja) |
GB (2) | GB201501334D0 (ja) |
PL (1) | PL3250245T3 (ja) |
PT (1) | PT3250245T (ja) |
RU (2) | RU2748124C2 (ja) |
SA (1) | SA517381997B1 (ja) |
WO (1) | WO2016120622A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2684150C (en) | 2007-05-14 | 2016-10-04 | Research Foundation Of State University Of New York | Decenoic acid dispersion inducers in the treatment of biofilms |
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
JP6151186B2 (ja) | 2010-12-08 | 2017-06-21 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | 創傷滲出液システム付属装置 |
JP5965409B2 (ja) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | 創傷滲出液を評価するための統合システム |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
CA2895896A1 (en) | 2012-12-20 | 2014-06-26 | Convatec Technologies Inc. | Processing of chemically modified cellulosic fibres |
EP3435941B1 (en) | 2016-03-30 | 2021-09-01 | ConvaTec Technologies Inc. | Detecting microbial infections in wounds |
BR112018070238A2 (pt) | 2016-03-30 | 2019-01-29 | Acib Gmbh | detecção de infecção microbiana em feridas |
KR20190028467A (ko) | 2016-07-08 | 2019-03-18 | 컨바텍 테크놀러지스 인크 | 체액 수집 장치 |
KR20190026858A (ko) | 2016-07-08 | 2019-03-13 | 컨바텍 테크놀러지스 인크 | 가요성 부압 시스템 |
ES2912094T3 (es) | 2016-07-08 | 2022-05-24 | Convatec Technologies Inc | Detección de flujo de fluidos |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN113507909A (zh) * | 2019-02-27 | 2021-10-15 | 希丝塔杰尼斯创伤护理有限公司 | 抗微生物敷料、敷料部件和方法 |
JP7511585B2 (ja) | 2019-06-03 | 2024-07-05 | コンバテック リミティド | 病原体を破壊して封じ込めるための方法およびデバイス |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2007716A3 (cs) * | 2007-10-15 | 2009-04-29 | Elmarco S. R. O. | Zpusob výroby nanovláken |
CN101239199A (zh) | 2008-03-18 | 2008-08-13 | 施建基(SHI/JianJi) | 自粘型壳聚糖止血膜及其制备方法 |
GB2463523B (en) | 2008-09-17 | 2013-05-01 | Medtrade Products Ltd | Wound care device |
US20100172889A1 (en) * | 2008-12-05 | 2010-07-08 | Catchmark Jeffrey M | Degradable biomolecule compositions |
WO2010107794A2 (en) * | 2009-03-16 | 2010-09-23 | University Of Memphis Research Foundation | Compositions and methods for delivering an agent to a wound |
RU2468129C2 (ru) * | 2010-12-30 | 2012-11-27 | Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный университет им. Н.Г. Чернышевского" | Биополимерное волокно, состав формовочного раствора для его получения, способ приготовления формовочного раствора, полотно биомедицинского назначения, способ его модификации, биологическая повязка и способ лечения ран |
WO2013064831A1 (en) * | 2011-11-01 | 2013-05-10 | Brightwake Limited | Wound dressings, and yarn useful therein |
GB201220076D0 (en) * | 2012-11-07 | 2012-12-19 | Medtrade Products Ltd | Wound care device |
EP3003026B1 (en) * | 2013-03-14 | 2019-07-17 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
CN103394119A (zh) * | 2013-07-10 | 2013-11-20 | 中国人民解放军第四军医大学 | 静电纺丝制备纳米仿生缓释型生物医用敷料的方法 |
-
2015
- 2015-01-27 GB GBGB1501334.5A patent/GB201501334D0/en not_active Ceased
-
2016
- 2016-01-27 JP JP2017557505A patent/JP6768705B2/ja active Active
- 2016-01-27 RU RU2017129871A patent/RU2748124C2/ru active
- 2016-01-27 BR BR112017016100-1A patent/BR112017016100B1/pt active IP Right Grant
- 2016-01-27 PT PT167075050T patent/PT3250245T/pt unknown
- 2016-01-27 AU AU2016210993A patent/AU2016210993B2/en active Active
- 2016-01-27 GB GB1601533.1A patent/GB2537010B/en active Active
- 2016-01-27 ES ES16707505T patent/ES2928794T3/es active Active
- 2016-01-27 PL PL16707505.0T patent/PL3250245T3/pl unknown
- 2016-01-27 WO PCT/GB2016/050180 patent/WO2016120622A1/en active Application Filing
- 2016-01-27 EP EP16707505.0A patent/EP3250245B8/en active Active
- 2016-01-27 CA CA2975018A patent/CA2975018A1/en not_active Abandoned
- 2016-01-27 KR KR1020177023030A patent/KR102608165B1/ko active IP Right Grant
- 2016-01-27 RU RU2021113700A patent/RU2021113700A/ru unknown
- 2016-01-27 CN CN201680011803.4A patent/CN107580507A/zh active Pending
- 2016-01-27 DK DK16707505.0T patent/DK3250245T3/da active
- 2016-01-27 US US15/546,641 patent/US10639202B2/en active Active
-
2017
- 2017-07-26 SA SA517381997A patent/SA517381997B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
ES2928794T3 (es) | 2022-11-22 |
EP3250245A1 (en) | 2017-12-06 |
RU2021113700A (ru) | 2021-06-25 |
EP3250245B1 (en) | 2022-06-22 |
RU2017129871A3 (ja) | 2019-08-13 |
AU2016210993B2 (en) | 2020-03-26 |
EP3250245B8 (en) | 2022-07-27 |
GB201601533D0 (en) | 2016-03-09 |
PL3250245T3 (pl) | 2022-12-19 |
CN107580507A (zh) | 2018-01-12 |
GB201501334D0 (en) | 2015-03-11 |
BR112017016100A2 (pt) | 2018-03-27 |
SA517381997B1 (ar) | 2021-08-29 |
JP2018502697A (ja) | 2018-02-01 |
US10639202B2 (en) | 2020-05-05 |
KR102608165B1 (ko) | 2023-11-29 |
CA2975018A1 (en) | 2016-08-04 |
WO2016120622A1 (en) | 2016-08-04 |
BR112017016100B1 (pt) | 2021-05-11 |
KR20170107493A (ko) | 2017-09-25 |
DK3250245T3 (da) | 2022-09-26 |
US20180014974A1 (en) | 2018-01-18 |
GB2537010A (en) | 2016-10-05 |
AU2016210993A1 (en) | 2017-08-17 |
RU2748124C2 (ru) | 2021-05-19 |
GB2537010B (en) | 2019-10-16 |
PT3250245T (pt) | 2022-09-28 |
RU2017129871A (ru) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6768705B2 (ja) | 創傷被覆材用の組成物 | |
JP6974177B2 (ja) | 創傷被覆材用の組成物 | |
JP6974176B2 (ja) | 創傷被覆材用の組成物 | |
RU2775940C2 (ru) | Композиция для раневых повязок |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190128 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190128 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200825 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200923 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6768705 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |